About Blue Jet Healthcare Limited
Blue Jet Healthcare is a speciality pharmaceutical and healthcare ingredients and intermediates company, offering niche products to innovator pharmaceutical companies and multinational generic pharmaceutical companies.
Since its incorporation in 1968, they have established a contract development and manufacturing organization (CDMO) business model (which provides critical ingredients to other pharma companies) in contrast media intermediates and high intensity sweeteners.
Contrast media is used in medical imaging and scans. Sweetners are used in pharma, beverages, personal care, confectionery and food industry.
Company operates in three product categories: (i) contrast media intermediates, (ii) high intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients (APIs).
ABOUT THE INDUSTRY
The global pharma formulation market is estimated at USD 1,381 billion and is expected to grow at a CAGR of 5-6% to reach USD 1,700 billion by 2027.
The size of the global contrast-media formulations market is approx USD 5.9 billion and forecasted to grow at a CAGR of 6-8% between 2023-2025. Growing population and changing demographics, lifestyle diseases, rising healthcare expenditure, focus on early diagnosis and preventive care are factors for growth for this segment.
The global high-intensity sweetener market is estimated to be USD 3 billion in size and estimated to grow at a CAGR of 6% to 7% over next 5 years due to growing rate of diabetes and obesity, shifting consumer preference and rising urbanization.
Why To Invest in Blue Jet Healthcare Limited
Large manufacturer of specialty pharmaceutical and healthcare ingredients, offering niche products to global innovator pharmaceutical companies.
The IPO proceeds will not be used by the company. It will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer.
Explore Other Products